A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score

The Lancet Gastroenterology and Hepatology

Volumn 4, Issue 1, 2019, Pages 63-70

  Jairath, Vipul ^a,b   Jeyarajah, Jenny ^a   Zou, Guangyong ^a,b   Parker, Claire E ^a   Olson, Allan ^c   Khanna, Reena ^a,b   D'Haens, Geert R ^d   Sandborn, William J ^e   Feagan, Brian G ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Receptos   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OZANIMOD; PLACEBO;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; COMPOSITE DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GEBOES SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO CLINIC STOOL FREQUENCY SUBSCORE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RECTUM HEMORRHAGE; ROBARTS HISTOPATHOLOGY INDEX; UC 100 SCORE; ULCERATIVE COLITIS; VALIDATION PROCESS; COMPLICATION; DRUG DEVELOPMENT; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; PATHOLOGY; REMISSION; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VALIDATION STUDY;

ADULT; COLITIS, ULCERATIVE; DRUG DEVELOPMENT; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 85058460834     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(18)30306-6     Document Type: Article

References (28)

1. Sandborn, WJ, Feagan, BG, Marano, C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
2. Sandborn, WJ, van Assche, G, Reinisch, W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265.
3. Reinisch, W, Sandborn, WJ, Hommes, DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60 (2011), 780–787.
4. Feagan, BG, Rutgeerts, P, Sands, BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
5. Rutgeerts, P, Sandborn, WJ, Feagan, BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
6. Sandborn, WJ, Feagan, BG, Marano, C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
7. Peyrin-Biroulet, L, Sandborn, W, Sands, BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
8. Higgins, PD, Schwartz, M, Mapili, J, Zimmermann, EM, Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol 100 (2005), 355–361.
9. Mosli, MH, Parker, CE, Nelson, SA, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev, 5, 2017 Cd011256.
10. Freemantle, N, Calvert, M, Wood, J, Eastaugh, J, Griffin, C, Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 289 (2003), 2554–2559.
11. Pammolli, F, Magazzini, L, Riccaboni, M, The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10 (2011), 428–438.
12. Sandborn, WJ, Feagan, BG, Wolf, DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374 (2016), 1754–1762.
13. Feagan, BG, Greenberg, GR, Wild, G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005), 2499–2507.
14. Mosli, MH, Feagan, BG, Zou, G, et al. Development and validation of a histological index for UC. Gut 66 (2017), 50–58.
15. Jairath, V, Khanna, R, Zou, GY, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther 42 (2015), 1200–1210.
16. Keir, M, Cabanski, C, Zhao, R, et al. Rectal bleeding accurately reflects mucosal inflammation in patients with ulcerative colitis. J Crohns Colitis 9 (2015), S137–S138.
17. Colombel, JF, Keir, ME, Scherl, A, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut 66 (2016), 2063–2068.
18. Peduzzi, P, Concato, J, Kemper, E, Holford, TR, Feinstein, AR, A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49 (1996), 1373–1379.
19. Labarere, J, Renaud, B, Fine, MJ, How to derive and validate clinical prediction models for use in intensive care medicine. Intensive Care Med 40 (2014), 513–527.
20. Steyerberg, EW, Bleeker, SE, Moll, HA, Grobbee, DE, Moons, KG, Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 56 (2003), 441–447.
21. Brier, SS, Analysis of contingency tables under cluster sampling. Biometrika 67 (1980), 591–596.
22. Nagelkerke, NJD, A note on a general definition of the coefficient of determination. Biometrika 78 (1991), 691–692.
23. Hosmer, DW, Lemeshow, S, A goodness-of-fit test for the multiple logistic regression model. Comm Stats A10 (1980), 1043–1069.
24. Efron, B, Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc 78 (1983), 316–331.
25. Deyo, RA, Diehr, P, Patrick, DL, Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12 (1991), 142S–158S.
26. Cohen, J, Staistical power analysis for the behavioral sciences. 2nd edn., 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
27. Hosmer, DW, Lemeshow, S, Assessing the fit of the model. Applied Logistic Regression. 2nd edn., 2005, John Wiley and Sons, New York, NY.
28. Altman, DG, Royston, P, The cost of dichotomising continuous variables. BMJ, 332, 2006, 1080.